Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 29 June 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Oncofetal gene SALL4 is a marker of aggressive hepatocellular carcinoma

This week's New England Journal of Medicine identifies a marker for a subclass of hepatocellular carcinoma with an aggressive phenotype.

News image

Hepatocellular carcinoma is the third leading cause of cancer-related deaths worldwide.

In the heterogeneous group of hepatocellular carcinomas, those with characteristics of embryonic stem-cell and progenitor-cell gene expression are associated with the worst prognosis.

The oncofetal gene SALL4, a marker of a subtype of hepatocellular carcinoma with progenitor-like features, is associated with a poor prognosis and is a potential target for treatment.

SALL4 is an oncofetal protein that is expressed in the human fetal liver
New England Journal of Medicine

Dr Kol Jia Yong and colleagues screened specimens obtained from patients with primary hepatocellular carcinoma for the expression of SALL4, and carried out a clinicopathological analysis.

Loss-of-function studies were then performed to evaluate the role of SALL4 in hepatocarcinogenesis, and its potential as a molecular target for therapy.

The research team assessed the therapeutic effects of a peptide that targets SALL4, and used in vitro functional and in vivo xenograft assays.

SALL4 is an oncofetal protein that is expressed in the human fetal liver and silenced in the adult liver, but it is reexpressed in a subgroup of patients who have hepatocellular carcinoma, and an unfavorable prognosis.

The team used gene-expression analysis to show the enrichment of progenitor-like gene signatures with overexpression of proliferative and metastatic genes in SALL4-positive hepatocellular carcinomas.

Loss-of-function studies confirmed the critical role of SALL4 in cell survival, and tumorigenicity.

Blocking SALL4–corepressor interactions released suppression of PTEN, and inhibited tumor formation in xenograft models in vivo.

Dr Yong's team concludes, "SALL4 is a marker for a progenitor subclass of hepatocellular carcinoma with an aggressive phenotype."

"The absence of SALL4 expression in the healthy adult liver enhances the potential of SALL4 as a treatment target in hepatocellular carcinoma."

N Engl J Med 2013; 368: 2266-2276
17 June 2013

Go to top of page Email this page Email this page to a colleague

 29 June 2016 
Progression to esophageal carcinoma in Barrett's
 29 June 2016 
Hep C eradication in people who inject drugs
 29 June 2016 
Anti-tumor necrosis factor in mothers and newborns
 28 June 2016 
Gastric cancer screening in the USA
 28 June 2016 
Acute severe ulcerative colitis
 28 June 2016 
Cancer recurrence after immune-suppressive therapies
 27 June 2016 
Epidemiology of NAFLD
 27 June 2016 
Tobacco smoking and ulcerative colitis
 27 June 2016 
The Toronto Consensus for H. pylori treatment
 24 June 2016 
Dietary trends in the USA
 24 June 2016 
Statins and colorectal cancer in IBD
 24 June 2016 
Fibre for chronic idiopathic constipation
 23 June 2016 
Biomarker for eosinophilic esophagitis diagnosis
 23 June 2016 
Touch screens in the IBD outpatient clinic
 23 June 2016 
Adverse events after colonoscopy bowel preparations
 22 June 2016 
Benefits and harms of colorectal cancer screening
 22 June 2016 
IBS symptoms in IBD
 22 June 2016 
Outcomes among US veterans with Hep B
 21 June 2016 
Screening for colorectal cancer
 21 June 2016 
Tenofovir and Hep B transmission in mothers
 21 June 2016 
Access to liver subspecialty care and survival
 20 June 2016 
Genes for colorectal cancer risk
 20 June 2016 
Patients and gastroenterologists’ perceptions on IBD
 20 June 2016 
Hep C treatment in people who inject drugs
 17 June 2016 
Noninvasive markers of liver fibrosis
 17 June 2016 
Predictors of starting with long-term PPIs
 17 June 2016 
Extrahepatic manifestations of Hep C
 16 June 2016 
Assessing progression of NAFLD
 16 June 2016 
Endotracheal intubation and endoscopy unit efficiency metrics
 16 June 2016 
Bile acid diarrhea
 15 June 2016 
Consensus for acute severe ulcerative colitis
 15 June 2016 
Dental erosions in GERD
 15 June 2016 
Pharmacological treatments for obesity with weight loss
 14 June 2016 
Antibiotics and gut inflammation
 14 June 2016 
Liver-related mortality in the developed world
 14 June 2016 
Hep C patient outcomes treated with different anti-viral regimens
 13 June 2016 
Obesity in the USA
 13 June 2016 
Celiac disease drug development
 13 June 2016 
Pneumonia risk in celiac disease
 10 June 2016 

Celiac disease drug development

 10 June 2016 
Rectal cancer surgery checklist
 10 June 2016 
Breath as a marker for IBS
 09 June 2016 
Psychological morbidity in young people with IBD
 09 June 2016 
Evaluation of endoscopic findings from patients with Crohn's
 09 June 2016 
Predicting hepatic encephalopathy in cirrhosis
 08 June 2016 
Adult obesity trends in the USA
 08 June 2016 
Pediatric IBD unclassified vs other IBD
 08 June 2016 
Dark chocolate and NASH oxidation
 07 June 2016 
Flexible endoscopy for Zenker's diverticulum
 07 June 2016 
Predicting risk of hepatic encephalopathy in cirrhosis
 07 June 2016 
Electronic learning system for colon capsule endoscopy
 06 June 2016 
Oral contraceptives and Crohn’s complications
 06 June 2016 
Disturbed sleep and symptoms in IBS
 06 June 2016 
Eosinophilic esophagitis
 03 June 2016 
Antibiotic prophylaxis in cirrhosis
 03 June 2016 
Mortality in hospitalized peptic ulcer patients
 03 June 2016 
Decision aid for surgical patients with ulcerative colitis
 02 June 2016 
Allergy tests for eosinophilic esophagitis
 02 June 2016 
Fatty liver disease and mortality
 02 June 2016 
Ethnic inequalities in rectal cancer care

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us